Given the concerns over how widely marketed Vytorin and Zetia were over the past few years, the FDA response to Genzyme and Isis raises an interesting thought - whether the agency is no longer willing to approve new drugs for wide use based solely on the ability to improve cholesterol. What do you think?
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments